SEC Filings

AVEXIS, INC. filed this Form 424B5 on 01/18/2018
Entire Document

Table of Contents

you will incur further dilution. Based on the public offering price of $102.00 per share, you will experience immediate dilution of $80.28 per share, representing the difference between the public offering price and our as adjusted net tangible book value per share as of September 30, 2017 after giving effect to this offering. See "Dilution".

The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock.

          The market price of our common stock has been, and is likely to continue to be, highly volatile. Since our initial public offering in February 2016, the intraday price of our common stock has fluctuated from a low of $16.11 to a high of $119.00. As a result of this volatility, you may not be able to sell your common stock at or above the price that you paid for it. The price of our common stock may continue to fluctuate substantially due to many factors, including:

    results of clinical trials of our product candidate or those of our competitors;

    the success of competitive products or technologies;

    commencement or termination of collaborations;

    regulatory or legal developments in the United States and other countries;

    developments or disputes concerning patent applications, issued patents or other proprietary rights;

    the recruitment or departure of key personnel;

    the level of expenses related to any of our product candidates or clinical development programs;

    the results of our efforts to discover, develop, acquire or in-license additional product candidates;

    actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;

    our manufacturing capabilities and strategy, including the scalability and commercial viability of our manufacturing methods and processes;

    our inability to obtain or delays in obtaining adequate product supply for any approved product or inability to do so at acceptable prices;

    disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

    significant lawsuits, including patent or stockholder litigation;

    variations in our financial results or those of companies that are perceived to be similar to us;

    changes in the structure of healthcare payment systems;

    market conditions in the pharmaceutical and biotechnology sectors;

    general economic, industry and market conditions; and

    the other factors described in this "Risk Factors" section and the risk factors included in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which are incorporated herein by reference.


© AveXis, Inc. All Rights Reserved.